Commonwealth of Pennsylvania Public School Empls Retrmt SYS Decreases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 83,052 shares of the medical device company's stock after selling 4,182 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS's holdings in DexCom were worth $6,459,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in DXCM. Versant Capital Management Inc bought a new position in shares of DexCom during the fourth quarter valued at $25,000. Private Trust Co. NA grew its position in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Larson Financial Group LLC raised its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter valued at approximately $38,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of DexCom during the 4th quarter worth about $49,000. Institutional investors own 97.75% of the company's stock.

DexCom Stock Down 3.7 %

Shares of DXCM traded down $2.66 during midday trading on Thursday, hitting $69.47. The company had a trading volume of 5,523,744 shares, compared to its average volume of 3,919,034. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $141.99. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $27.15 billion, a P/E ratio of 48.58, a P/E/G ratio of 2.30 and a beta of 1.28. The company's 50-day simple moving average is $82.96 and its 200-day simple moving average is $77.07.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the topic of several research analyst reports. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup boosted their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.82.

Insider Activity at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the firm's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 over the last 90 days. Company insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.